1 / 7

Psoriasis - Plaque Psoriasis

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients

guest100846
Télécharger la présentation

Psoriasis - Plaque Psoriasis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Psoriasis - Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm One-Stop Shop for Business Information

  2. Summary Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics. 

  3. In the last couple of years, the face of healthcare has been changing due to challenges – quality and its affordability and accessibility to the providers and patients. We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

  4. Table Of Contents • Executive Summary • Unmet Need in Psoriasis • Specific Unmet Need and Emerging Therapies • Pipeline – Biologics Products • Pipeline – Oral Treatment • Pipeline – Topical Treatments • Commercial Outlook • Disease Overview • Current Treatment Options • Treatment Guidelines

  5. Related Reports • Growth, Trends and Forecast, 2013 - 2019 • Global Dermatological Drugs Market 2014-2018 • Global Generic Drugs Market 2014-2018 • Sinopharm Medicine Holding Guoda Chain Drugstore Co Ltd in Consumer Health (China) • Ophthalmic Drugs: Data, Analysis and Forecasts to 2024

  6. Custom Research Incase the reports don’t match your requirement then we can do a Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us at a unique position to take up Custom Research demands of yours. We provide the specifications of the custom research job to a dedicated team comprising of researchers, analysts and industry experts, who have close experience and understanding of global markets, competitive landscapes, various business models, market shares, drivers, restraints and benchmarks.

  7. To know more :Psoriasis - Plaque Psoriasis & Psoriatic Arthritis : Novel Oral drugs and Biologics to Change Future Treatment Paradigm Contact Us:-Call India: +91-22-27810772/73 Call USA/Canada (Toll Free): 1-866-279-8368 Email id : info@bharatbook.com

More Related